Test Price
2,800 AED✅ Home Collection Available
LRBA Gene Immunodeficiency Common Variable Type 8 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Clinical Excellence & UAE Regulatory Assurance
- Diagnostic Precision: 99.9% analytical sensitivity via ISO 9001:2015 certified NGS workflow, ensuring accurate LRBA variant detection including copy-number variants.
- Premium Home Collection: Complimentary VIP mobile phlebotomy using ISO-certified cold-chain transport, available 8 AM – 11 PM across all Emirates.
- Post-Test Clinical Guidance: Complimentary telephonic consultation with our DHA-licensed medical genetics team to contextualize your results.
- Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
- Turnaround Time: 3–4 weeks from sample receipt to comprehensive clinical report.
Test Overview & Methodology
This genetic test sequences the entire coding region and exon-intron boundaries of the LRBA gene (lipopolysaccharide-responsive beige-like anchor protein) using Next-Generation Sequencing (NGS) on the Illumina® platform. Copy-number variant (CNV) analysis is performed concurrently to detect large deletions or duplications. Pathogenic variants are interpreted according to ACMG/AMP guidelines and correlate with Common Variable Immunodeficiency type 8 (CVID8).
| Feature | Our Test (Best-in-Class) | Closest Alternative |
|---|---|---|
| Methodology | Full gene NGS (Illumina®) with CNV analysis | Sanger sequencing (single-exon, lower sensitivity) |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Analytical Sensitivity | 99.9% | ~95% |
| Variant Interpretation | ACMG/AMP 2026 guidelines with DHA-certified clinical report | Basic variant list, limited clinical interpretation |
Physician Insight & Safety Protocols
"The LRBA genetic test provides a definitive molecular diagnosis for CVID8 in patients presenting with early-onset autoimmunity, enteropathy, and recurrent sinopulmonary infections. Identification of biallelic pathogenic variants enables targeted management including hematopoietic stem cell transplantation consideration. However, results must always be correlated with lymphocyte subset analysis, immunoglobulin quantitation, and family history. A negative sequencing result does not rule out LRBA deficiency if clinical suspicion persists — whole exome sequencing may be warranted. Collaboration with a clinical immunologist remains essential for comprehensive care."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
⚠️ Important Precautions
Never discontinue or adjust prescribed immunosuppressive agents, biologic therapies, or replacement immunoglobulin without explicit guidance from your treating immunologist. Abrupt interruptions can lead to severe infectious complications or autoimmune flares. Always consult your physician before making any medication changes based on genetic results.
Exclusion Criteria & Emergency Red Flags
- Active, untreated severe infection (e.g., sepsis, meningitis) — postpone genetic sampling until clinical stability is achieved.
- Known severe allergy to venipuncture materials or active bleeding diathesis — discuss alternative sample collection methods with your referring physician.
- If you experience signs of anaphylaxis, severe respiratory distress, or loss of consciousness after sample collection, seek immediate emergency care at the nearest hospital.
- Genetic testing is not a substitute for emergency medical intervention; always follow your immunologist's advice for acute symptoms.
Patient FAQ & Clinical Guidance
1. What is the diagnostic yield of this LRBA gene test for suspected CVID8?
This NGS test identifies biallelic pathogenic variants in approximately 95% of patients with clinical and immunological features consistent with LRBA deficiency. The inclusion of CNV analysis further increases detection rate by capturing large exonic deletions that Sanger sequencing would miss. A negative result does not exclude the diagnosis if clinical suspicion remains high.
2. Can I use a dried blood spot (FTA card) for this test, and is it as accurate as a venous blood draw?
Yes, a single drop of blood on an FTA card is a validated, non-invasive sample type that yields DNA of sufficient quantity and quality for NGS analysis. The card must be stored at room temperature in a dry environment, protected from direct sunlight and humidity. Results from FTA cards are equivalent to those from whole blood when processed in our ISO 9001:2015 certified laboratory.
3. How do UAE regulations protect my genetic data and test results?
All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your sample and genomic data are encrypted, anonymized post-analysis, and never shared with third parties without your explicit written consent. Results are retained for a period compliant with UAE healthcare data retention laws and then securely destroyed.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates under DHA Facility License 1143 and adheres to the UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic testing is performed in our CAP-accredited laboratory in Dubai Healthcare City under strict confidentiality and data security protocols.
Clinical & Logistical Metadata
| Test Name | LRBA Gene Immunodeficiency Common Variable Type 8 Genetic Test (NGS + CNV) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or dried blood spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (Illumina®) with CNV analysis; ACMG/AMP variant interpretation |
| ICD-10-CM Code | D83.8 (Common variable immunodeficiency, other) |
| LOINC Code | 81315-1 (LRBA gene mutation analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians